Cargando…

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss

The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has dramatically improved over the last decade; however, patients with visceral metastases are still faced with poor outcomes. Phosphatase and tensin homolog (PTEN) loss is observed in 40%–60% of mCRPC patients and is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Myint, Zin W., Allison, Derek B., Ellis, Carleton S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495426/ https://www.ncbi.nlm.nih.gov/pubmed/34631559 http://dx.doi.org/10.3389/fonc.2021.731002

Ejemplares similares

Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis
por: Collette, Kaylyn R., et al.
Publicado: (2022)

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
por: Kmak, Jamie A., et al.
Publicado: (2020)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
por: Mitsui, Yozo, et al.
Publicado: (2023)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Isolated peritoneal carcinomatosis from metastatic castration-resistant prostate cancer and associated biliary obstruction: A case report
por: Couture, Félix, et al.
Publicado: (2018)

Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN
por: Guo, Xi, et al.
Publicado: (2022)

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
por: Maslov, Diana V., et al.
Publicado: (2023)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015)

Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
por: Zhao, Dongsheng, et al.
Publicado: (2023)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Spontaneous Remission of Metastatic Castration-Resistant Prostate Cancer: Coley’s Toxin Revisited?
por: Choe, Albert, et al.
Publicado: (2022)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2020)

Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
por: Leaning, Darren, et al.
Publicado: (2023)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
por: Colombo, Carla, et al.
Publicado: (2022)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
por: Wenzel, Mike, et al.
Publicado: (2021)

Castration-resistant prostate cancer with metastasis to external auditory canal – Case report
por: Akagi, Naoki, et al.
Publicado: (2022)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer
por: Skelton, William P, et al.
Publicado: (2020)

Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis
por: Mulati, Yelin, et al.
Publicado: (2021)

Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment
por: Uemura, Hiroji, et al.
Publicado: (2021)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wei, ZhenHeng, et al.
Publicado: (2021)

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
por: Raju, Rachel, et al.
Publicado: (2021)

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
por: Sigorski, Dawid, et al.
Publicado: (2023)

Ureteral metastasis from locally invasive, castrate-resistant prostate cancer: A Case report
por: Janatpour, Zachary C., et al.
Publicado: (2021)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t9v4vimqndujg7umibkkd73ksq